Related references
Note: Only part of the references are listed.Predictors of dose escalation of adalimumab in a prospective cohort of Crohn's disease patients
E. Bultman et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2012)
Direct medical cost of managing IBD patients: A Canadian population-based study
Charles N. Bernstein et al.
INFLAMMATORY BOWEL DISEASES (2012)
Loss of Response and Need for Adalimumab Dose Intensification in Crohn's Disease: A Systematic Review
Vincent Billioud et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2011)
Body Mass Index and Clinical Response to Infliximab in Rheumatoid Arthritis
Ruth Klaasen et al.
ARTHRITIS AND RHEUMATISM (2011)
Prevalence and Epidemiology of Overweight and Obesity in Children with Inflammatory Bowel Disease
Millie D. Long et al.
INFLAMMATORY BOWEL DISEASES (2011)
Association Between Adiposity in Midlife and Older Age and Risk of Diabetes in Older Adults
Mary L. Biggs et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2010)
Top-down therapy for IBD: rationale and requisite evidence
Geert R. D'Haens
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2010)
Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease.
Jean Frederic Colombel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
The Placebo Response Rate in Irritable Bowel Syndrome and Inflammatory Bowel Disease
Bruce E. Sands
DIGESTIVE DISEASES (2009)
Effects of tumor necrosis factor alpha inhibition with infliximab on lipid levels and insulin resistance in patients with inflammatory bowel disease
Ioannis E. Koutroubakis et al.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY (2009)
Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort
F. Schnitzler et al.
GUT (2009)
Effect of anti-tumor necrosis factor-α therapies on body mass index in patients with psoriasis
Rosita Saraceno et al.
PHARMACOLOGICAL RESEARCH (2008)
Infliximab restores glucose Homeostasis in an animal model of diet-induced obesity and diabetes
Eliana P. Araujo et al.
ENDOCRINOLOGY (2007)
Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease
Severine Vermeire et al.
GUT (2007)
Clinical pharmacokinetics and use of infliximab
Ulrich Klotz et al.
CLINICAL PHARMACOKINETICS (2007)
The impact of increased body mass index on the clinical course of Crohn's disease
DJ Hass et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2006)
Infliximab for induction and maintenance therapy for ulcerative colitis
P Rutgeerts et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Infliximab maintenance therapy for fistulizing Crohn's disease
BE Sands et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
An analysis of factors influencing short-term and sustained response to infliximab treatment for Crohn's disease
IDR Arnott et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2003)
Predictors of response to infliximab in patients with Crohn's disease
MA Parsi et al.
GASTROENTEROLOGY (2002)
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial
SB Hanauer et al.
LANCET (2002)
Crohn's disease clinical course and severity in obese patients
A Blain et al.
CLINICAL NUTRITION (2002)
Share Paper
